Back

Identifying the vulnerable: navigating the predictors of implantable cardioverter defibrillator (ICD) therapy in the moderately reduced ejection fraction (EF) cohort

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Ventricular arrhythmias risk stratification Device Treatment EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Mahmoud Abdelfattah

Aswan Heart Centre, Aswan (Egypt)

6 More presentations in this session

Presentation thumbnail
Machine learning-based prediction of drug-induced QTc changes in a large Finnish biobank cohort
Doctor V. Langen (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Characteristics of patients with mitral valve prolapse presenting with sudden cardiac arrest: a single-center case-control study
Doctor N. Martini (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Effect of flecainide on complex ventricular arrhythmogenesis: insights from the prospective UNIFLECA study
Doctor M. Botis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Gender differences in risk of sudden cardiac arrest in patients with newly diagnosed non-ischemic cardiomyopathy or coronary artery disease: targeted insights from the SCD-PROTECT study
Professor D. Duncker (Hannover, DE)
Abstract Slides Video
Presentation thumbnail
Risk of inherited cardiac disease in relatives of out-of-hospital cardiac arrest patients - a nationwide study
Ms M. Brun Nielsen (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular arrhythmias risk stratification

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Session
The role of the primary prevention defibrillator after myocardial infarction in the era of modern heart failure therapy: the PROFID project
thumbnail
Congress Presentation
Personalised precision or pragmatic population approach for sudden cardiac death prevention in heart failure?
thumbnail
Congress Presentation
Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources